Interplay between mTOR and STAT5 signaling modulates the balance between regulatory and effective T cells

Immunobiology

Volumn 220, Issue 4, 2015, Pages 510-517

  Shan, Juan ^a,b   Feng, Li ^a   Sun, Guixiang ^a   Chen, Peng ^a   Zhou, Yanni ^a   Xia, Mengjuan ^a   Li, Hongsheng ^a   Li, Youping ^a,c  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^b SICHUAN UNIVERSITY   (China)

^c Chinese Evidence Based Medicine Centre   (China)

Author keywords

Immune balance; MicroRNA 155; MTOR signaling; Rapamycin; Regulatory T cell; STAT5 signaling

Indexed keywords

ANTAGOMIR; CD28 ANTIBODY; CD3 ANTIBODY; CD4 ANTIGEN; INITIATION FACTOR 4E BINDING PROTEIN 1; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; JANUS KINASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA 155; PROTEIN ANTIBODY; RAPAMYCIN; STAT5 PROTEIN; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; MICRORNA; MIRN155 MICRORNA, MOUSE; PROTEIN BINDING; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CD4+CD25+ REGULATORY T LYMPHOCYTE; CD4+CD25- EFFECTIVE T LYMPHOCYTE; CELL SELECTION; CONTROLLED STUDY; DEVELOPMENTAL STAGE; ENZYME INHIBITION; GENE EXPRESSION; GENETIC TRANSFECTION; IMMUNOMODULATION; IMMUNOREGULATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TRANSCRIPTION REGULATION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; METABOLISM; PHENOTYPE;

ANIMALS; FORKHEAD TRANSCRIPTION FACTORS; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; MALE; MICE; MICRORNAS; PHENOTYPE; PROTEIN BINDING; SIGNAL TRANSDUCTION; SIROLIMUS; STAT5 TRANSCRIPTION FACTOR; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TOR SERINE-THREONINE KINASES;

EID: 84925110650     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2014.10.020     Document Type: Article

References (24)

1. + T cell suppressor function. J. Immunol. 2004, 172:6519-6523.
2. + regulatory T cell homeostasis and the maintenance of self-tolerance. J. Immunol. 2003, 171:3435-3441.
3. Basu S., Golovina T., Mikheeva T., et al. Cutting edge: Foxp3-mediated induction of Pim-2 allows human T regulatory cells to preferentially expand in Rapamycin. J. Immunol. 2008, 180:5794-5798.
4. + regulatory T cells. Blood 2005, 105:4743-4748.
5. + regulatory T cells. J. Immunol. 2004, 172:5287-5296.
6. Bestard O., Cassis L., Cruzado J.M., Torras J., Franquesa M., Gil-Vernet S., et al. Costimulatory blockade with mTor inhibition abrogates effector T-cell responses allowing regulatory T-cell survival in renal transplantation. Transpl. Int. 2011, 24(5):451-460.
7. Ekong U.D., Mathew J., Melin-Aldana H., Wang D., Alonso E.M. Successful resolution of inflammation and increased regulatory T cells in sirolimus-treated post-transplant allograft hepatitis. Pediatr. Transplant. 2012, 16(2):165-175.
8. Gabryšová L., Christensen J.R., Wu X. Integrated T-cell receptor and costimulatory signals determine TGF-b-dependent differentiation and maintenance of Foxp31 regulatory T cells. Eur. J. Immunol. 2011, 41:1242-1248.
9. Golovina T.N., Mikheeva T., Suhoski M.M., et al. CD28 costimulation is essential for human T regulatory expansion and function. J. Immunol. 2008, 181:2855-2868.
10. Hendrikx T.K., Van Gurp E.A.F.J., Sewgobind V.D.K.D., Mol W.M., Schoordijk W., Klepper M., et al. Generation of donor-specific regulatory t-cell function in kidney transplant patients. Transplantation 2009, 87(3):376-383.
11. Jiang S., Zhang H.W., Lu M.H., He X.H., Li Y., Gu H., Liu M.F., Wang E.D. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res. 2010, 70(April (8)):3119-3127.
12. + regulatory T cells in ex vivo-expanded CD25-enriched products from healthy donors and patients with multiple sclerosis. Cytotherapy 2007, 9(2):144-157.
13. Lu L.F., Thai T.H., Calado D.P., Chaudhry A., Kubo M., et al. Foxp3- dependent microRNA155 confers competitive fitness to regulatory T cells by targeting SOCS1 protein. Immunity 2009, 30:80-91.
14. + T cells. Cell. Immunol. 2012, 273:85-93.
15. Mizuki M.J., Schwable C., Steur C., et al. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. Blood 2003, 101:3164-3173.
16. - effector T cells. Int. Immunol. 2007, 20(3):421-431.
17. Rodriguez A., Vigorito E., Clare S., Warren M.V., Couttet P., et al. Requirement of bic/microRNA-155 for normal immune function. Science 2007, 316:608-611.
18. Ruggenenti P., Perico N., Gotti E., Cravedi P., D'Agati V., Gagliardini E., et al. Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury. Transplantation 2007, 84(8):956-964.
19. + regulatory T cells cultured with Rapamycin. J. Immunol. 2007, 178:320-329.
20. Strauss L., Czystowska M., et al. Differential responses of human regulatory T cells (Treg) and effector T cells to Rapamycin. PLoS ONE 2009, 4(6):e5994.
21. Wang Y., Camirand G., Lin Y., et al. Regulatory T cells require mammalian target of rapamycin signaling to maintain both homeostasis and alloantigen-driven proliferation in lymphocyte-replete mice. J. Immunol. 2011, 186:2809-2818.
22. White E. The pims and outs of survival signaling: role for the Pim-2 protein kinase in the suppression of apoptosis by cytokines. Genes Dev. 2003, 17:1813-1816.
23. Yao R., Ma Y.L., Liang W., Li H.H., Ma Z.J., Yu X., Liao Y.H. MicroRNA-155 modulates Treg and Th17 cells differentiation and Th17 cell function by targeting SOCS1. PLoS ONE 2012, 7(10):e4608.
24. + T cells. Blood 2008, 111:453-462.